Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC

May 30th 2020

The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E-Mutant CRC

May 30th 2020

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

Dr. Pishvaian on FDA Approval of Atezolizumab Plus Bevacizumab in HCC

May 29th 2020

Michael J. Pishvaian, MD, PhD, discusses the FDA approval of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with hepatocellular carcinoma (HCC).

FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC

May 29th 2020

The FDA has approved atezolizumab plus bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC

May 29th 2020

Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.

FDA Grants Onvansertib Fast Track Designation in KRAS+ mCRC

May 28th 2020

The FDA has granted Fast Track designation to onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

Dr. Mizrahi on Targeting Treatment in Metastatic Colorectal Cancer

May 28th 2020

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Dr. Le on Research Needed to Address Unmet Needs in mCRC

May 27th 2020

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Dr. Raghav on the Utility of ctDNA in CRC

May 27th 2020

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

FDA Grants Trastuzumab Deruxtecan Orphan Drug Status in Gastric Cancer

May 22nd 2020

The FDA has granted an orphan drug designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Dr. Harding on Exciting Research Efforts in the Pipeline for HCC

May 22nd 2020

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 22nd 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Harding on Exciting Research Efforts in the Pipeline for HCC

May 21st 2020

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Dr. Parikh on the Role of Radiation in HCC

May 21st 2020

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Dr. Hidalgo Medina on Promising Research in Pancreatic Cancer

May 20th 2020

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Hidalgo Medina on Promising Research in Pancreatic Cancer

May 19th 2020

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting pancreatic cancer research presented at the 2020 ACCR Virtual Annual Meeting I.

Primary Location of GEJ Tumors Affects Treatment

May 18th 2020

Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.